Definitive characterization of CA 19-9 in resectable pancreatic cancer using a reference set of serum and plasma specimens

Brian B. Haab, Ying Huang, Seetharaman Balasenthil, Katie Partyka, Huiyuan Tang, Michelle Anderson, Peter Allen, Aaron Sasson, Herbert Zeh, Karen Kaul, Doron Kletter, Shaokui Ge, Marshall Bern, Richard Kwon, Ivan Blasutig, Sudhir Srivastava, Marsha L. Frazier, Subrata Sen, Michael A Hollingsworth, Jo Ann RinaudoAnn M. Killary, Randall E. Brand

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The validation of candidate biomarkers often is hampered by the lack of a reliable means of assessing and comparing performance. We present here a reference set of serum and plasma samples to facilitate the validation of biomarkers for resectable pancreatic cancer. The reference set includes a large cohort of stage I-II pancreatic cancer patients, recruited from 5 different institutions, and relevant control groups. We characterized the performance of the current best serological biomarker for pancreatic cancer, CA 19-9, using plasma samples from the reference set to provide a benchmark for future biomarker studies and to further our knowledge of CA 19-9 in early-stage pancreatic cancer and the control groups. CA 19-9 distinguished pancreatic cancers from the healthy and chronic pancreatitis groups with an average sensitivity and specificity of 70-74%, similar to previous studies using all stages of pancreatic cancer. Chronic pancreatitis patients did not show CA 19-9 elevations, but patients with benign biliary obstruction had elevations nearly as high as the cancer patients. We gained additional information about the biomarker by comparing two distinct assays. The two CA 9-9 assays agreed well in overall performance but diverged in measurements of individual samples, potentially due to subtle differences in antibody specificity as revealed by glycan array analysis. Thus, the reference set promises be a valuable resource for biomarker validation and comparison, and the CA 19-9 data presented here will be useful for benchmarking and for exploring relationships to CA 19-9.

Original languageEnglish (US)
Article numbere0139049
JournalPloS one
Volume10
Issue number10
DOIs
StatePublished - Oct 2 2015

Fingerprint

pancreatic neoplasms
Biomarkers
Pancreatic Neoplasms
biomarkers
Plasmas
Serum
Benchmarking
pancreatitis
Chronic Pancreatitis
Assays
cholestasis
Control Groups
Antibody Specificity
assays
sampling
Polysaccharides
polysaccharides
Sensitivity and Specificity
neoplasms
Antibodies

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Haab, B. B., Huang, Y., Balasenthil, S., Partyka, K., Tang, H., Anderson, M., ... Brand, R. E. (2015). Definitive characterization of CA 19-9 in resectable pancreatic cancer using a reference set of serum and plasma specimens. PloS one, 10(10), [e0139049]. https://doi.org/10.1371/journal.pone.0139049

Definitive characterization of CA 19-9 in resectable pancreatic cancer using a reference set of serum and plasma specimens. / Haab, Brian B.; Huang, Ying; Balasenthil, Seetharaman; Partyka, Katie; Tang, Huiyuan; Anderson, Michelle; Allen, Peter; Sasson, Aaron; Zeh, Herbert; Kaul, Karen; Kletter, Doron; Ge, Shaokui; Bern, Marshall; Kwon, Richard; Blasutig, Ivan; Srivastava, Sudhir; Frazier, Marsha L.; Sen, Subrata; Hollingsworth, Michael A; Rinaudo, Jo Ann; Killary, Ann M.; Brand, Randall E.

In: PloS one, Vol. 10, No. 10, e0139049, 02.10.2015.

Research output: Contribution to journalArticle

Haab, BB, Huang, Y, Balasenthil, S, Partyka, K, Tang, H, Anderson, M, Allen, P, Sasson, A, Zeh, H, Kaul, K, Kletter, D, Ge, S, Bern, M, Kwon, R, Blasutig, I, Srivastava, S, Frazier, ML, Sen, S, Hollingsworth, MA, Rinaudo, JA, Killary, AM & Brand, RE 2015, 'Definitive characterization of CA 19-9 in resectable pancreatic cancer using a reference set of serum and plasma specimens', PloS one, vol. 10, no. 10, e0139049. https://doi.org/10.1371/journal.pone.0139049
Haab, Brian B. ; Huang, Ying ; Balasenthil, Seetharaman ; Partyka, Katie ; Tang, Huiyuan ; Anderson, Michelle ; Allen, Peter ; Sasson, Aaron ; Zeh, Herbert ; Kaul, Karen ; Kletter, Doron ; Ge, Shaokui ; Bern, Marshall ; Kwon, Richard ; Blasutig, Ivan ; Srivastava, Sudhir ; Frazier, Marsha L. ; Sen, Subrata ; Hollingsworth, Michael A ; Rinaudo, Jo Ann ; Killary, Ann M. ; Brand, Randall E. / Definitive characterization of CA 19-9 in resectable pancreatic cancer using a reference set of serum and plasma specimens. In: PloS one. 2015 ; Vol. 10, No. 10.
@article{58c7ba8e54534c7a8bfcfa294ae219ff,
title = "Definitive characterization of CA 19-9 in resectable pancreatic cancer using a reference set of serum and plasma specimens",
abstract = "The validation of candidate biomarkers often is hampered by the lack of a reliable means of assessing and comparing performance. We present here a reference set of serum and plasma samples to facilitate the validation of biomarkers for resectable pancreatic cancer. The reference set includes a large cohort of stage I-II pancreatic cancer patients, recruited from 5 different institutions, and relevant control groups. We characterized the performance of the current best serological biomarker for pancreatic cancer, CA 19-9, using plasma samples from the reference set to provide a benchmark for future biomarker studies and to further our knowledge of CA 19-9 in early-stage pancreatic cancer and the control groups. CA 19-9 distinguished pancreatic cancers from the healthy and chronic pancreatitis groups with an average sensitivity and specificity of 70-74{\%}, similar to previous studies using all stages of pancreatic cancer. Chronic pancreatitis patients did not show CA 19-9 elevations, but patients with benign biliary obstruction had elevations nearly as high as the cancer patients. We gained additional information about the biomarker by comparing two distinct assays. The two CA 9-9 assays agreed well in overall performance but diverged in measurements of individual samples, potentially due to subtle differences in antibody specificity as revealed by glycan array analysis. Thus, the reference set promises be a valuable resource for biomarker validation and comparison, and the CA 19-9 data presented here will be useful for benchmarking and for exploring relationships to CA 19-9.",
author = "Haab, {Brian B.} and Ying Huang and Seetharaman Balasenthil and Katie Partyka and Huiyuan Tang and Michelle Anderson and Peter Allen and Aaron Sasson and Herbert Zeh and Karen Kaul and Doron Kletter and Shaokui Ge and Marshall Bern and Richard Kwon and Ivan Blasutig and Sudhir Srivastava and Frazier, {Marsha L.} and Subrata Sen and Hollingsworth, {Michael A} and Rinaudo, {Jo Ann} and Killary, {Ann M.} and Brand, {Randall E.}",
year = "2015",
month = "10",
day = "2",
doi = "10.1371/journal.pone.0139049",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Definitive characterization of CA 19-9 in resectable pancreatic cancer using a reference set of serum and plasma specimens

AU - Haab, Brian B.

AU - Huang, Ying

AU - Balasenthil, Seetharaman

AU - Partyka, Katie

AU - Tang, Huiyuan

AU - Anderson, Michelle

AU - Allen, Peter

AU - Sasson, Aaron

AU - Zeh, Herbert

AU - Kaul, Karen

AU - Kletter, Doron

AU - Ge, Shaokui

AU - Bern, Marshall

AU - Kwon, Richard

AU - Blasutig, Ivan

AU - Srivastava, Sudhir

AU - Frazier, Marsha L.

AU - Sen, Subrata

AU - Hollingsworth, Michael A

AU - Rinaudo, Jo Ann

AU - Killary, Ann M.

AU - Brand, Randall E.

PY - 2015/10/2

Y1 - 2015/10/2

N2 - The validation of candidate biomarkers often is hampered by the lack of a reliable means of assessing and comparing performance. We present here a reference set of serum and plasma samples to facilitate the validation of biomarkers for resectable pancreatic cancer. The reference set includes a large cohort of stage I-II pancreatic cancer patients, recruited from 5 different institutions, and relevant control groups. We characterized the performance of the current best serological biomarker for pancreatic cancer, CA 19-9, using plasma samples from the reference set to provide a benchmark for future biomarker studies and to further our knowledge of CA 19-9 in early-stage pancreatic cancer and the control groups. CA 19-9 distinguished pancreatic cancers from the healthy and chronic pancreatitis groups with an average sensitivity and specificity of 70-74%, similar to previous studies using all stages of pancreatic cancer. Chronic pancreatitis patients did not show CA 19-9 elevations, but patients with benign biliary obstruction had elevations nearly as high as the cancer patients. We gained additional information about the biomarker by comparing two distinct assays. The two CA 9-9 assays agreed well in overall performance but diverged in measurements of individual samples, potentially due to subtle differences in antibody specificity as revealed by glycan array analysis. Thus, the reference set promises be a valuable resource for biomarker validation and comparison, and the CA 19-9 data presented here will be useful for benchmarking and for exploring relationships to CA 19-9.

AB - The validation of candidate biomarkers often is hampered by the lack of a reliable means of assessing and comparing performance. We present here a reference set of serum and plasma samples to facilitate the validation of biomarkers for resectable pancreatic cancer. The reference set includes a large cohort of stage I-II pancreatic cancer patients, recruited from 5 different institutions, and relevant control groups. We characterized the performance of the current best serological biomarker for pancreatic cancer, CA 19-9, using plasma samples from the reference set to provide a benchmark for future biomarker studies and to further our knowledge of CA 19-9 in early-stage pancreatic cancer and the control groups. CA 19-9 distinguished pancreatic cancers from the healthy and chronic pancreatitis groups with an average sensitivity and specificity of 70-74%, similar to previous studies using all stages of pancreatic cancer. Chronic pancreatitis patients did not show CA 19-9 elevations, but patients with benign biliary obstruction had elevations nearly as high as the cancer patients. We gained additional information about the biomarker by comparing two distinct assays. The two CA 9-9 assays agreed well in overall performance but diverged in measurements of individual samples, potentially due to subtle differences in antibody specificity as revealed by glycan array analysis. Thus, the reference set promises be a valuable resource for biomarker validation and comparison, and the CA 19-9 data presented here will be useful for benchmarking and for exploring relationships to CA 19-9.

UR - http://www.scopus.com/inward/record.url?scp=84947294520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947294520&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0139049

DO - 10.1371/journal.pone.0139049

M3 - Article

C2 - 26431551

AN - SCOPUS:84947294520

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e0139049

ER -